<DOC>
	<DOCNO>NCT02099617</DOCNO>
	<brief_summary>The main objective SENIOR study establish efficacy safety everolimus elute stent biodegradable abluminal polymer ( SYNERGY II ) associate short dual antiplatelet therapy ( DAPT ) patient ≥75 year old , suffer stable angina , silent ischemia ( 1 month DAPT ) acute coronary syndrome ( 6 month DAPT ) relate significant coronary artery disease require percutaneous coronary intervention . The primary end point demonstrate SYNERGY II patient ≥75 year old associate low rate composite rate major cardiovascular cerebrovascular event ( all-cause death , myocardial infarction , stroke , ischemia-driven target lesion revascularization ) similar risk stent thrombosis bare metal stent one year .</brief_summary>
	<brief_title>Efficacy Safety New Generation Drug Eluting Stents Associated With Ultra Short Duration Dual Antiplatelet Therapy . Design Short Duration Dual antiplatElet Therapy With SyNergy II Stent Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization .</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>1 Patient ≥ 75 year old 2 One significant coronary artery stenosis is/are present ( defined ≥70 % visual assessment ≥50 % Fractional Flow Reserve &lt; 0.80 ) leave main coronary stenosis ≥50 % visual assessment ) suitable PCI one follow present : Silent ischemia , stressinduced myocardial ischemia ≥ 10 % myocardium asymptomatic patient stressinduced myocardial ischemia &lt; 10 % myocardium AND FFR ( Fractional Flow Reserve ) ≤0.80 b Stable angina , patient objective ischemia despite optimal medical therapy c acute coronary syndrome include : unstable angina , non ST ST elevation myocardial infarction . 3 All patient must also sign informed consent per local law comply study process follow least one year . 1 The subject eligible randomization ANY follow present : 2 Indication myocardial revascularization coronary artery bypass grafting , 3 Subjects unable tolerate , obtain comply dual antiplatelet therapy least one month ( stable angina silent ischemia ) least six month ( acute coronary syndrome ) , 4 Subjects require additional surgery ( cardiac noncardiac ) within one month , 5 Non cardiac comorbidities life expectancy le 1 year , 6 Prior hemorrhagic stroke , 7 Known allergy aspirin P2Y12 inhibitor , 8 At least one contra indication ALL authorize P2Y12 inhibitor request dose ( case contra indication one two P2Y12 inhibitor , investigator allow use P2Y12 inhibitor allergy know ) . 9 Silent ischemia &lt; 10 % myocardium FFR ≥0.80 . 10 Participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>